公司资料
Novavax 股价、新闻与催化剂
- 股票代码:
- NVAX
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
10.00 USD (+6.95%)
收盘价
最后更新: 2026年9月17日
1.68B USD
市值
股价为何变动
截至 2026年9月17日，NVAX 上涨 6.95%，收于 $10.00。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
业务概览
Novavax is a vaccine company centered on protein-based immunization and respiratory-disease programs. Its story has been shaped by the challenge of turning platform science into durable commercial execution.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, Novavax sits in specialty vaccine biotechnology.
商业模式特征
The business depends on vaccine demand, partnerships, regulatory progress, and the ability to sustain a post-pandemic franchise.
生物医药行业定位
Novavax is a vaccine catalyst name where commercial and regulatory updates can quickly shift sentiment.
未来催化剂
- Novavax's catalysts are the COVID/flu-combo program, seasonal-vaccine partnerships, and royalty momentum from its vaccine platform. The company still needs the platform to keep broadening.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。